Samsung invests in Generate: Biomedicines to advance AI-driven protein therapeutics discovery
- Samsung Life Science Fund invests in Generate:Biomedicines, a Flagship Pioneering company leading in AI-enabled protein therapeutics discovery and development - Investment highlights Samsung's dedication to advancing innovation and creating a robust ecosystem for AI-enabled therapeutic develop...
Samsung Biologics listed among top most sustainable companies in Dow Jones Sustainability World Index
* Acknowledged for strong environmental, social, and governance (ESG) performance and continued commitment to sustainability through net-zero initiatives and responsible value chain management INCHEON, South Korea, Dec. 16, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contr...
Samsung Biologics hosts ESG event with suppliers to strengthen decarbonization efforts
INCHEON, South Korea, Dec. 3, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today hosted its second Supplier ESG Day to share insights on sustainable management and encourage ESGactions among suppliers. Second of i...
Samsung Biologics signs manufacturing deal with European pharmaceutical company
* The company will provide manufacturing services through 2031 in deals worth overUSD 668 million * Samsung Biologics' cumulative contract value for 2024 surpasses USD 4 billion with latest deals INCHEON, South Korea, Nov. 20, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global ...
Samsung Biologics earns ISO certifications in recognition of business excellence
* The company adds new ISO certification for compliance management and certified to updated standards for information and cloud security * Certifications recognize Samsung Biologics' commitment to operational excellence and demonstrates the company's reliability and integrity as a trusted CDM...
Samsung Biologics reports third quarter 2024 financial results
* Recorded Q3'24 consolidated revenue of KRW 1.2 trillion * Recorded Q3'24 consolidated operating profit of KRW 338.6 billion * Continued business expansion through strong competitive edge in speed and execution INCHEON, South Korea, Oct. 23, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 2079...
Samsung Biologics launches high-concentration formulation platform to accelerate high-dose drug development
* S-HiConTM is designed to maximize drug delivery and stability through high-concentration formulation * The platform can address challenges associated with viscosity and achieve stable liquid formulation for over 200 mg/mL subcutaneous administration INCHEON, South Korea, Oct. 14, 2024 /PRNe...
Samsung Biologics launches development platforms for enhanced therapeutic efficacy
* Samsung Biologics showcases new innovative development platforms – S-AfuCHO TM and S-OptiChargeTM – at BioProcess International 2024 * New technology platforms to proactively address evolving industry trends and enable high-quality development INCHEON, South Korea, Sept. 25, 2024 /PRNewswire...
Samsung Biologics joins the Pharmaceutical Supply Chain Initiative as Supplier Partner
* Samsung Biologics to embed PSCI principles into business practices for responsible value chain management * Supplier Partnership reaffirms company's commitment to decarbonize and build resilient supply chains INCHEON, South Korea, Aug. 6, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940....
Samsung Biologics Reports First Quarter 2024 Financial Results
* Recorded Q1'24 consolidated revenue of KRW 946.9 billion * Recorded Q1'24 consolidated operating profit of KRW 221.3 billion * Sustained growth driven by ongoing strategic expansion in capacity and portfolio INCHEON, South Korea, April 24, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 20794...
Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance
INCHEON, South Korea, Sept. 17, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced today a new agreement with Bristol Myers Squibb (NYSE: BMY) for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug substance. Bristol Myers Squibb and Samsung Biolog...
Samsung Biologics appoints new leadership to oversee quality and regulatory affairs
- Distinguished industry leaders with extensive track records in quality assurance and regulatory affairs join Samsung Biologics to support the company's quality-driven business operation. INCHEON, South Korea, Aug. 23, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract d...
Samsung Biologics Reports Second Quarter 2023 Financial Results
* Recorded Q2'23 consolidated revenue of KRW 866.2 billion * Recorded Q2'23 consolidated operating profit of KRW 253.4 billion * Achieved record-high semi-annual revenue exceeding KRW 1,587.1 billion * Strong growth sustained with successful contract wins and full completion of Plant 4 set ...
Samsung Biologics releases 2023 ESG Report, reaffirming its commitment to net-zero progress and corporate social responsibility
INCHEON, South Korea, July 18, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940), a global contract development and manufacturing organization (CDMO), today released its 2023 Environmental, Social and Governance (ESG) Report. The annual report outlines the company's progress toward its sustain...
Samsung Biologics accelerates timeline of new fifth plant to be operational by April 2025
- Marking the first phase of the company's second Bio Campus, Plant 5 is expected to have shortest construction timeline - Samsung Biologics will maintain the world's largest biomanufacturing capacity at 784,000 liters upon completion of the newest plant - Key features of Plant 5 include seamless ...
Samsung Biologics Reports First Quarter 2023 Financial Results
* Recorded Q1'23 consolidated revenue of KRW 720.9 billion. * Recorded Q1'23 consolidated operating profit of KRW 191.7 billion. * Expected to maintain a strong growth trajectory with the full utilization of existing and newly expanded capacities. INCHEON, South Korea, April 24, 2023 /PRNews...
Samsung Biologics announces construction of Plant 5 to commence Bio Campus II capacity expansion
* The company plans to begin construction in the first half of 2023 and commence operations in 2025 * As part of Samsung Biologics' second Bio Campus, Plant 5 will hold a manufacturing capacity of 180,000 liters, expanding the company's total site capacity to 784,000 liters upon its completio...
Samsung Biologics Reports Fourth Quarter & Fiscal Year 2022 Financial Results
* Q4'22 consolidated revenue of KRW 965.5 billion and Q4'22 operating profit ofKRW 312.8 billion. * FY'22 consolidated revenue of KRW 3.00 trillion and FY'22 operating profit ofKRW 983.6 billion. * Strong growth momentum expected to continue with active expansions in capacity, geography, an...
Samsung Biologics receives the Terra Carta Seal in recognition of the company's commitment to creating a sustainable future
* Samsung Biologics is one of 19 companies to have been awarded the 2022 Terra Carta Seal. * The Terra Carta Seal recognises global companies which are driving innovation and demonstrating their commitment to, and momentum towards, the creation of genuinely sustainable markets. * Designed b...
Samsung Biologics Reports Third Quarter 2022 Financial Results
* Recorded consolidated revenue of KRW 873 billion in Q3'22 * Recorded consolidated operating profit of KRW 324.7 billion in Q3'22 * Started partial operations at Plant 4 within 23 months since groundbreaking as previously committed and launched two new development platforms INCHEON, South K...
